NovoCure (NVCR) Is Down 5.7% After Q3 Revenue Growth and Expanded International Coverage — Has the Growth Story Changed?

• On October 30, 2025, NovoCure reported its third quarter earnings, posting US$167.2 million in revenue, an 8% increase from a year earlier, alongside a higher net loss of US$37.27 million and progress in expanding European and Asian market access.
• One unique insight from the report was the company’s positive national coverage decision in Spain and regulatory advances for its tumor treating fields therapy, reflecting increased international recognition and broader adoption potential for its technology.
• We'll explore how NovoCure’s strong quarterly revenue growth and new international coverage agreements impact the company's future growth narrative.

Rare earth metals are the new gold rush. Find out which 37 stocks are leading the charge.

NovoCure Investment Narrative Recap

NovoCure shareholders are putting their faith in expanding global access to Tumor Treating Fields technology and successful reimbursement in new markets to unlock long-term value, despite ongoing losses and uncertain profitability. The latest Q3 results reinforce the company’s international footprint with new European coverage and steady revenue growth, but the near-term catalyst remains securing broader reimbursement while the major risk continues to be persistent negative net income; the recent news does not materially change these dynamics.

Among recent announcements, Spain’s decision to provide national coverage for TTFields therapy marks a relevant step toward validation and improved revenue stability. This regulatory win aligns with the company’s efforts to grow its presence outside the US, yet short-term performance will still depend on how quickly these agreements drive recurring sales in new indications.

In contrast, investors should be aware of how ongoing losses and the unclear timeline to profitability could weigh on sentiment if...

Read the full narrative on NovoCure (it's free!)

NovoCure's narrative projects $863.5 million revenue and $107.8 million earnings by 2028. This requires 11.1% yearly revenue growth and a $278.8 million earnings increase from current earnings of -$171.0 million.

Uncover how NovoCure's forecasts yield a $25.19 fair value, a 97% upside to its current price.

Exploring Other Perspectives

Simply Wall St Community fair value estimates for NovoCure range from US$25.19 to US$48.27, with three distinct viewpoints. While new coverage decisions add promise, persistent losses mean you should consider a number of informed opinions before drawing conclusions.

Explore 3 other fair value estimates on NovoCure - why the stock might be worth just $25.19!

Build Your Own NovoCure Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your NovoCure research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.
• Our free NovoCure research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate NovoCure's overall financial health at a glance.

Curious About Other Options?

Our daily scans reveal stocks with breakout potential. Don't miss this chance:

• AI is about to change healthcare. These 33 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• Find companies with promising cash flow potential yet trading below their fair value.
• These 16 companies survived and thrived after COVID and have the right ingredients to survive Trump's tariffs. Discover why before your portfolio feels the trade war pinch.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com